SANDRA STARR: Open Payments
NPI 1831363894 · MILAN, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,455 in 83 payments from 11 companies in 2025. Trend: 2023 $2,350 · 2024 $1,788 · 2025 $1,455
Food & beverage: $1,455
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 18 | $345 |
| Lundbeck LLC | 8 | $190 |
| ABBVIE INC. | 14 | $182 |
| Janssen Pharmaceuticals, Inc | 11 | $173 |
| Teva Pharmaceuticals USA, Inc. | 13 | $173 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $152 |
| Neurocrine BioSciences, Inc. | 5 | $97 |
| Alkermes, Inc. | 2 | $58 |
| Vanda Pharmaceuticals Inc. | 2 | $45 |
| E.R. Squibb & Sons, L.L.C. | 1 | $21 |
Products named: REXULTI, ABILIFY ASIMTUFII, VRAYLAR, INVEGA SUSTENNA, CAPLYTA, UZEDY, INGREZZA, ARISTADA.
Industry payments across TN — which companies pay providers there.
